{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:04:38Z","timestamp":1770822278286,"version":"3.50.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathologie Biologie"],"published-print":{"date-parts":[[2004,6]]},"DOI":"10.1016\/j.patbio.2004.03.017","type":"journal-article","created":{"date-parts":[[2004,6,12]],"date-time":"2004-06-12T16:41:09Z","timestamp":1087058469000},"page":"289-293","source":"Crossref","is-referenced-by-count":7,"title":["Risk of leukemic transformation in PV and ET patients"],"prefix":"10.1016","volume":"52","author":[{"given":"Christine","family":"Chomienne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Didier","family":"Rain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Bri\u00e8re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.patbio.2004.03.017_BIB1","first-page":"600","article-title":"Juvenile chronic myelomonocytic leukemias: molecular and novel therapeutic basis","volume":"45","author":"Chomienne","year":"1997","journal-title":"Pathol Biol"},{"key":"10.1016\/j.patbio.2004.03.017_BIB2","doi-asserted-by":"crossref","first-page":"10560","DOI":"10.1073\/pnas.92.23.10560","article-title":"Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder","volume":"92","author":"Nagata","year":"1995","journal-title":"Proc Nat Acad Sci USA"},{"issue":"5","key":"10.1016\/j.patbio.2004.03.017_BIB3","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1182\/blood.V90.5.2057","article-title":"Two new EPO receptor mutations: truncated EPO receptors are most frequently associated with primary familial and congenital polycythemias","volume":"90","author":"Kralovics","year":"1997","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.patbio.2004.03.017_BIB4","doi-asserted-by":"crossref","first-page":"18502","DOI":"10.1182\/blood.V87.4.1502.bloodjournal8741502","article-title":"Missense mutation of the erythropoietin receptor is a rare event in human erythroid malignancies","volume":"87","author":"Le Couedic","year":"1996","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.patbio.2004.03.017_BIB5","first-page":"447","article-title":"Mutation in the negative regulatory element of the erythropoietin receptor gene in a case of sporadic primary polycythemia","volume":"22","author":"Sokol","year":"1994","journal-title":"Exp Hematol"},{"issue":"1)(Suppl 1","key":"10.1016\/j.patbio.2004.03.017_BIB6","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1053\/shem.2003.50028","article-title":"Therapeutic strategies for chromic myeloid leukemia in the chronic (stable) phase","volume":"40","author":"Goldman","year":"2003","journal-title":"Semin Hematol"},{"issue":"3","key":"10.1016\/j.patbio.2004.03.017_BIB7","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1080\/17843286.1993.11718304","article-title":"Von Recklinghausen neurofibromatosis and hematologic malignancies: 2\u00a0case reports in adulthood","volume":"48","author":"Van Baren","year":"1993","journal-title":"Acta Clin Belg"},{"issue":"2","key":"10.1016\/j.patbio.2004.03.017_BIB8","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/ng1156","article-title":"Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia","volume":"34","author":"Tartaglia","year":"2003","journal-title":"Nat Genet"},{"issue":"13","key":"10.1016\/j.patbio.2004.03.017_BIB9","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N Engl J Med"},{"issue":"1)(Suppl 1","key":"10.1016\/j.patbio.2004.03.017_BIB10","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1053\/shem.2003.50027","article-title":"Etiology of the myeloproliferative disorders: the role of thrombopoietin","volume":"40","author":"Kanshansky","year":"2003","journal-title":"Semin Hematol"},{"issue":"1","key":"10.1016\/j.patbio.2004.03.017_BIB11","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1046\/j.1365-2141.1996.00297.x","article-title":"Proto-oncogene c-mpl is involved in spontaneous megakaryocytopoiesis in myeloproliferative disorders","volume":"92","author":"Li","year":"1996","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.patbio.2004.03.017_BIB12","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1182\/blood.V100.2.714","article-title":"The expression pattern of c-mpl in megakaryocytes correlates with thrombotic risk in essential thrombocythemia","volume":"100","author":"Teofili","year":"2002","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.patbio.2004.03.017_BIB13","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/blood.V82.3.877.877","article-title":"Expression of the c-mpl proto-oncogene in human hematolog malignancies","volume":"82","author":"Vigon","year":"1993","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.patbio.2004.03.017_BIB14","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1182\/blood-2002-03-0949","article-title":"Biochemical characterization of PRV-1, a novel hematopoietic cell surface receptor, which is overexpressed in polycythemia rubra vera","volume":"100","author":"Klippel","year":"2002","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.patbio.2004.03.017_BIB15","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1182\/blood-2002-07-2287","article-title":"Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin","volume":"101","author":"Liu","year":"2003","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.patbio.2004.03.017_BIB16","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/gcc.1195","article-title":"Fusion of the BCR and the fibroblast growth factor receptor-1 (FGFR1) genes as a result of t(8;22)(p11;q11) in a myeloproliferative disorder: the first fusion gene involving BC but not ABL","volume":"32","author":"Fioretos","year":"2001","journal-title":"Genes Chromosomes Cancer"},{"issue":"4","key":"10.1016\/j.patbio.2004.03.017_BIB17","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1046\/j.1365-2141.2001.03215.x","article-title":"Mutation and methylation analysis of the transforming growth factor beta receptor II gene in polycythaemia vera","volume":"115","author":"Li","year":"2001","journal-title":"Br J Haematol"},{"issue":"3\u20134","key":"10.1016\/j.patbio.2004.03.017_BIB18","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000015025","article-title":"Cannizzaro la; FHIT gene transcript alterations occur frequently in myeloproliferative and myelodysplastic diseases","volume":"81","author":"Luan","year":"1998","journal-title":"Cytogenet Cell Genet"},{"key":"10.1016\/j.patbio.2004.03.017_BIB19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.leu.2402725","article-title":"Possible dominant-negative mutation of the SHIP gene in acute myeloid leukaemia","volume":"17","author":"Luo","year":"2003","journal-title":"Leukemia"},{"issue":"1\u20132","key":"10.1016\/j.patbio.2004.03.017_BIB20","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0303-7207(01)00489-0","article-title":"Alterations of the insulin-like growth factor system in patient with polycythemia vera","volume":"181","author":"Michl","year":"2001","journal-title":"Mol Cell Endocrimol"},{"issue":"4","key":"10.1016\/j.patbio.2004.03.017_BIB21","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1182\/blood-2002-06-1843","article-title":"Mutations in the VHL gene in sporadic apparently congenital polycythemia","volume":"101","author":"Pastore","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.patbio.2004.03.017_BIB22","first-page":"132","article-title":"Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols","volume":"23","author":"Berk","year":"1986","journal-title":"Semin Hematol"},{"key":"10.1016\/j.patbio.2004.03.017_BIB23","first-page":"102","article-title":"Treatment of polycythemia vera: a summary of clinical trials conducted by the Polycythemia Vera Study Group","author":"Berk","year":"1995"},{"key":"10.1016\/j.patbio.2004.03.017_BIB24","first-page":"167","article-title":"Long-Term management of polycythemia vera with hydroxyurea: a progress report","volume":"23","author":"Kaplan","year":"1986","journal-title":"Semin Hematol"},{"issue":"1(Suppl 1)","key":"10.1016\/j.patbio.2004.03.017_BIB25","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1053\/shem.2003.50030","article-title":"Indications for lowering platelet numbers in essential thrombocythemia","volume":"40","author":"Barbui Tiziano","year":"2003","journal-title":"Semin Hematol"},{"issue":"1","key":"10.1016\/j.patbio.2004.03.017_BIB26","first-page":"6","article-title":"The very long-term evolution of polycythemia vera: an analysis of 318\u00a0patients initially treated by phlebotomy or 32P between 1969 and 1981","volume":"34","author":"Najean","year":"1997","journal-title":"Semin Hematol"},{"key":"10.1016\/j.patbio.2004.03.017_BIB27","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood.V89.7.2319","article-title":"Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461\u00a0patients greater than 65\u00a0years of age","volume":"89","author":"Najean","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.patbio.2004.03.017_BIB28","first-page":"167","article-title":"Long-Term management of polycythemia vera with hydroxyurea: a progress report","volume":"23","author":"Kaplan","year":"1986","journal-title":"Semin Hematol"},{"issue":"9","key":"10.1016\/j.patbio.2004.03.017_BIB29","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood.V90.9.3370","article-title":"Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292\u00a0patients under the age of 65\u00a0years","volume":"90","author":"Najean","year":"1997","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.patbio.2004.03.017_BIB30","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/(SICI)1097-0142(19980915)83:6<1205::AID-CNCR21>3.0.CO;2-8","article-title":"Long term treatment of myeloproliferative disease with interferon-alpha-2b: feasibility and efficacy","volume":"83","author":"Gilbert","year":"1998","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.patbio.2004.03.017_BIB31","first-page":"40","article-title":"Interferon alfa: effects of long-term treatment for polycythemia vera","volume":"34","author":"Silver","year":"1997","journal-title":"Semin Hematol"},{"issue":"20","key":"10.1016\/j.patbio.2004.03.017_BIB32","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1056\/NEJM198805193182002","article-title":"Anagrelide: a new drug for treating thrombocytosis","volume":"318","author":"Silverstein","year":"1988","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.patbio.2004.03.017_BIB33","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V97.4.863","article-title":"Long-term use of anagrelide in young patients with essential thrombocythemia","volume":"97","author":"Storen","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.patbio.2004.03.017_BIB34","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJM198102193040801","article-title":"Increased incidence of acute leukaemia in polycythemia vera associated with chlorambucil therapy","volume":"304","author":"Berk","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1016\/j.patbio.2004.03.017_BIB35","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.1984.2.6.558","article-title":"Efficacy trial of pipobroman in polycythemia vera and incidence of acute leukaemia","volume":"2","author":"Brusamolino","year":"1984","journal-title":"J Clim Oncol"},{"key":"10.1016\/j.patbio.2004.03.017_BIB36","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/bjc.1981.150","article-title":"Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomised trial. Leukemia and Hematosarcoma","volume":"44","year":"1981","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.patbio.2004.03.017_BIB37","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1046\/j.1365-2141.2000.02188.x","article-title":"Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial","volume":"110","author":"Finazzi","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.patbio.2004.03.017_BIB38","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood.V91.2.616","article-title":"Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p delection","volume":"91","author":"Sterkers","year":"1998","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.patbio.2004.03.017_BIB39","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/(SICI)1098-2264(199708)19:4<250::AID-GCC7>3.0.CO;2-W","article-title":"Genetic lesions associated with blastic transformation of polycythemia vera and essential thrombocythemia","volume":"19","author":"Giadano","year":"1997","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.patbio.2004.03.017_BIB40","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/BF02982131","article-title":"Leukemogenic risk of hydroxyurea therapy as a single agent in polycythemia vera and essential thrombocythemia: N-and K-ras mutations and microsatellite instability in chromosomes 5\u00a0and 7\u00a0in 69\u00a0patients","volume":"75","author":"Mavrogianni","year":"2002","journal-title":"Int J Hematol"},{"issue":"3\u20134","key":"10.1016\/j.patbio.2004.03.017_BIB41","first-page":"183","article-title":"Leukemic transformation in three patients with polycythemia vera. Analysis of the clinicopathological features and N-ras gene mutation","volume":"27","author":"Sakai","year":"1996","journal-title":"J Med"},{"issue":"5","key":"10.1016\/j.patbio.2004.03.017_BIB42","first-page":"389","article-title":"Leukemic transformation of polycythemia vera after treatment with hydroxyurea with abnormalities of chromosome 17","volume":"48","author":"Tothova","year":"2001","journal-title":"Neoplasma"},{"issue":"2","key":"10.1016\/j.patbio.2004.03.017_BIB43","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0165-4608(90)90057-H","article-title":"Translocation t(3;21)(q26;q22) in acute myeloblastic leukemia secondary to polycythemia vera","volume":"44","author":"Dastugue","year":"1990","journal-title":"Cancer Genet Cytogenet"},{"issue":"1","key":"10.1016\/j.patbio.2004.03.017_BIB44","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/0165-4608(94)90071-X","article-title":"Translocation (3;21)(q26;q22) in therapy-related myelodysplasie following drugs targeting DNA-topoisomerase II combined with alkylating agents, and in myeloproliferative disorders undergoing spontaneous leukemic transformation","volume":"76","author":"Pedersen-Bjergaard","year":"1994","journal-title":"Cancer Genet Cytogenet"},{"issue":"1","key":"10.1016\/j.patbio.2004.03.017_BIB45","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S0165-4608(02)00628-3","article-title":"Trisomy 8\u00a0as the sole chromosomal aberration in myelocytic malignancies: a multicolour and locus-specific fluorescence in situ hybridisation study","volume":"140","author":"Paulsson","year":"2003","journal-title":"Cancer Genet Cytogenet"},{"issue":"1","key":"10.1016\/j.patbio.2004.03.017_BIB46","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood-2002-11-3343","article-title":"Clinical-cytogenetic associations in 306\u00a0patients with therapy-related myelodysplasia and myeloid leukemia: The University of Chicago series","volume":"102","author":"Smith","year":"2003","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.patbio.2004.03.017_BIB47","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1182\/blood-2003-03-0744","article-title":"Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders","volume":"102","author":"Kralovics","year":"2003","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.patbio.2004.03.017_BIB48","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/0165-4608(93)90123-4","article-title":"Age- and gender-related heterogeneity of cancer chromosome aberrations","volume":"70","author":"Mertens","year":"1993","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.patbio.2004.03.017_BIB49","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0955-0674(03)00002-4","article-title":"Oxidant signals and oxidative stress","volume":"15","author":"Finkel","year":"2003","journal-title":"Curr Opin Cell Biol"}],"container-title":["Pathologie Biologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0369811404000951?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0369811404000951?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T12:05:53Z","timestamp":1585829153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0369811404000951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["S0369811404000951"],"URL":"https:\/\/doi.org\/10.1016\/j.patbio.2004.03.017","relation":{},"ISSN":["0369-8114"],"issn-type":[{"value":"0369-8114","type":"print"}],"subject":[],"published":{"date-parts":[[2004,6]]}}}